Blackstone and Alnylam Partner in RNAi Deal Worth up to $2 Billion

, , , , , , , , ,

Investment firm Blackstone Life Sciences and Alnylam Pharmaceuticals announced a broad strategic collaboration worth up to $2 billion.

Read more
/by